Helicobacter

Papers
(The TQCC of Helicobacter is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults45
Effects of non‐viableLactobacillus reutericombining with 14‐day standard triple therapy onHelicobacter pylorieradication: A randomized double‐blind placebo‐controlled trial37
Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study37
Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection31
PPI‐amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta‐analysis30
Transmission routes and patterns of helicobacter pylori30
An overview of traditional Chinese medicine therapy for Helicobacter pylori–related gastritis28
CRISPR‐based detection of Helicobacter pylori in stool samples28
Helicobacter pylori induces gastric cancer via down‐regulating miR‐375 to inhibit dendritic cell maturation26
The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta‐analysis25
Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta‐analysis25
Impact of smoking on the eradication of Helicobacter pylori24
Helicobacter pylori infection and the progression of atherosclerosis: A systematic review and meta‑analysis23
Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short‐chain fatty acids in Helicobacter pylori‐infected mice23
Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China23
Association between bacteria other than Helicobacter pylori and the risk of gastric cancer22
The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota—a double‐blind, placebo‐controlled, randomiz22
Whole family—based Helicobacter pylori eradication is a superior strategy to single‐infected patient treatment approach: A systematic review and meta‐analysis21
Influence of Helicobacter pylori infection on PD‐1/PD‐L1 blockade therapy needs more attention21
Efficacy of eradication therapy in Helicobacter pylori‐negative gastric mucosa‐associated lymphoid tissue lymphoma: A meta‐analysis21
Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice21
Probiotics mitigate Helicobacter pylori‐induced gastric inflammation and premalignant lesions in INS‐GAS mice with the modulation of gastrointestinal microbiota21
Quadruple therapy with vonoprazan 20 mg daily as a first‐line treatment for Helicobacter pylori infection: A single‐center, open‐label, noninferiority, randomized controlled trial20
Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy20
Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing19
Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in RUSSIA: The data of real‐world national multicenter trial19
Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis19
Helicobacter pylori infection is associated with the co‐occurrence of bacteria in the oral cavity and the gastric mucosa19
Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in19
Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori18
Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through multiple molecular actions18
Transmission ofHelicobacter pyloribetween a human and two dogs: A case report17
Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections—Exploratory study17
The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing17
Helicobacter pylori infection and risk of cardiovascular disease16
Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study16
Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high‐risk area for gastric cancer in northwest China: An all‐ages population‐based cross‐sectional study16
Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross‐sectional study15
Extracellular vesicles from helicobacter pylori‐infected cells and helicobacter pylori outer membrane vesicles in atherosclerosis15
Perspectives from recent advances of Helicobacter pylori vaccines research15
Application of WeChat platform in the management of patients infected with Helicobacter pylori15
Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study15
Gastric organoids: Advancing the study of H. pylori pathogenesis and inflammation15
The recurrence rate ofHelicobacter pyloriin recent 10 years: A systematic review and meta‐analysis15
Pepsinogen II in gastritis and Helicobacter pylori infection15
Immune evaluation of aSaccharomyces cerevisiae‐based oral vaccine againstHelicobacter pyloriin mice15
Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non‐Helicobacter pylori Helicobacter infection: A study of 50 cases at a single facility in Japan15
Cardia and non‐cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta‐analysis, and estimation of population attributable fraction15
Association between Helicobacter pylori infection and growth outcomes in children: A meta‐analysis15
Helicobacter pylori and the intestinal microbiome among healthy school‐age children15
Association betweenHelicobacter pyloriantibodies determined by multiplex serology and gastric cancer risk: A meta‐analysis14
Long term impact of vonoprazan‐based Helicobacter pylori treatment on gut microbiota and its relation to post‐treatment body weight changes14
Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost‐effectiveness analysis14
Dynamic changes in antibiotic resistance genes and gut microbiota afterHelicobacter pylorieradication therapies14
TikTok and Bilibili as sources of information on Helicobacter pylori in China: A content and quality analysis14
10‐Day and 14‐day high‐dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis14
Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐lineHelicobacter pylorieradication regimen13
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐l13
Helicobacter pylori infection and risk of multiple sclerosis: An updated meta‐analysis13
Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost‐effectiveness analysis12
Adherence to Maastricht V/Florence consensus report for the management ofHelicobacter pyloriinfection among primary care physicians and medical students in Croatia: A cross‐sectional study12
Helicobacter pylori knowledge and perception among multi‐ethnic Asians12
Long noncoding RNA NEAT1 promotes tumorigenesis in H. pylori gastric cancer by sponging miR‐30a to regulate COX‐2/BCL9 pathway12
Investigation of endoscopic findings in nine cases of Helicobacter suis‐infected gastritis complicated by gastric mucosa‐associated lymphoid tissue lymphoma12
Both family‐based Helicobacter pylori infection control and management strategy and screen‐and‐treat strategy are cost‐effective for gastric cancer prevention12
Long‐term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children12
Prevalence estimates of Helicobacter species infection in pancreatic and biliary tract cancers11
Efficacy and safety of bismuth‐based quadruple therapy forHelicobacterpylorieradication in children11
Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter?11
Effect of enhanced patient instructions onHelicobacter pylorieradication: A systematic review and meta‐analysis of randomized controlled trials11
Declining trends of prevalence ofHelicobacter pyloriinfection and incidence of gastric cancer in Taiwan: An updated cross‐sectional survey and meta‐analysis11
Helicobacter pylori‐positive chronic atrophic gastritis and cellular senescence11
Application of molecular techniques inHelicobacter pyloridetection: limitations and improvements11
Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny11
New regimens as first‐line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial11
YouTube as a source of information on Helicobacter pylori: Content and quality analysis10
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea10
“True” Helicobacter pylori infection and non‐cardia gastric cancer: A pooled analysis within the Stomach Cancer Pooling (StoP) Project10
Efficacy of bismuth added to standard triple therapy as the first‐line eradication regimen for Helicobacter pylori infection10
Does technology‐enhanced communication improve Helicobacter pylori eradication outcomes?—A meta‐analysis10
Doxycycline and minocycline inHelicobacter pyloritreatment: A systematic review and meta‐analysis10
Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double‐blind, placebo‐controlled trial10
Tetracycline‐levofloxacin versus amoxicillin‐levofloxacin quadruple therapies in the second‐line treatment of Helicobacter pylori infection10
Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines10
Heat‐killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll‐like receptor 49
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study9
AI‐2 represses CagA expression and bacterial adhesion, attenuating the Helicobacter pylori‐induced inflammatory response of gastric epithelial cells9
Comparison of clinical outcomes and FOXP3, IL‐17A responses in Helicobacter pylori infection in children versus adults9
Helicobacter pylori treatment knowledge, access and barriers: A cross‐sectional study9
Influences ofHelicobacter pyloriinfection on diversity, heterogeneity, and composition of human gastric microbiomes across stages of gastric cancer development9
Cholesterol glucosylation–based survival strategy in Helicobacter pylori9
Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication9
Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study9
Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy9
Saccharomyces boulardii CNCM I‐745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy8
Age of eradication and failure rates of clarithromycin‐containing triple therapy forHelicobacter pylori: A 15‐year population‐based study8
Consistency of Helicobacter pylori eradication rates of first‐line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years8
Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 20208
Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis8
Lessons learned from upper gastrointestinal endoscopy in asymptomatic Chinese8
Antibiotic resistance, heteroresistance, and eradication success ofHelicobacter pyloriinfection in children8
Dietary multivalent anti‐Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients8
Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta‐analysis and critical analysis8
Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin‐resistant using intragastric fluid8
Clinicopathological features of nodular gastritis in three classes of age8
Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole‐genome sequencing‐based study in Southern China8
0.033082008361816